Company Profile

BioMarin Pharmaceutical Inc
Profile last edited on: 12/20/22      CAGE: 4C7J0      UEI: HDEGEX3YK7H1

Business Identifier: Drugs for orphan diseases: therapies for rare genetic diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

770 Lindaro Street
San Rafael, CA 94901
   (415) 884-6700
Location: Multiple
Congr. District: 02
County: Marin

Public Profile

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The company's approved products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used to treat genetic disease called mucopolysaccharidosis (MPS)VI; Kuvan tablet, a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); Aldurazyme, which is used to treat mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase; and Firdapse, an orphan drug for the treatment of lambert eaton myasthenic syndrome. Its other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is under Phase II clinical development for the treatment of PKU; GALNS (N-acetylgalactosamine 6-sulfatase), which is under in Phase I/II clinical development for the treatment of MPS IVA; and BMN 195, a Phase I clinical development product for the treatment of duchenne muscular dystrophy. The company is also conducting preclinical development of various other enzyme product candidates for genetic and other metabolic diseases, including BMN-185, an IgA protease for IgA nephropathy; and BMN-103, a glucosidase for pompe disease. In addition, BioMarin holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. The company sells its products to specialty pharmacies, hospitals acting as retailers, pharmaceutical wholesalers, and distributors throughout the world. BioMarin has a strategic alliance with Merck Serono S.A. and collaboration with Genzyme Corporation

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 2 NIH $1,733,352
Project Title: Production of Beta-Glucuronidase For MPS VII
1998 1 NIH $100,000
Project Title: Optically Activated Genetic Therapies

Key People / Management

  Jean-Jacques Bienaime -- President

  Jeffrey Robert Ajer -- Chief Commercial Officer and Exec. VP

  Robert A Baffi -- Exec. VP of Technical Operations

  Jon T Conary

  Henry J Fuchs -- Chief Medical Officer and Exec. VP

  Emil D Kakkis

  Daniel K Spiegelman -- Chief Financial Officer and Exec. VP